Introduction
============

Lung cancer is one of the most common malignancies and is the leading cause of cancer-related death in Denmark, as well as worldwide.[@b1-clep-4-039]--[@b3-clep-4-039] In Denmark, incidence rates of lung cancer in 2009 were 83 (men) and 64 (women) per 100,000 person-years. Lung cancer is classified into two subtypes, including small cell (SCLC, 15%--18% of incident cases) and non-small cell lung cancer (NSCLC, 82%--85% of incident cases) based on histopathology and differences in prognosis and treatment. Stages of SCLC (limited and extensive) and NSCLC (I--IV) are assigned according to TNM classification, which addresses tumor size and growth into neighboring organs (T), lymph node involvement (N), and distant metastases (M). Prognosis and treatment choices vary according to cancer stage, but prognosis is also affected by age and level of comorbidity.[@b4-clep-4-039]--[@b8-clep-4-039] The five-year survival rate for SCLC patients is approximately 20% for limited disease and 0% for extensive disease.[@b9-clep-4-039] Corresponding rates for NSCLC patients are 50% and approximately 5% for stage IA and IV, respectively.[@b10-clep-4-039],[@b11-clep-4-039] Only two studies have been conducted regarding the registration of TNM staging for lung cancer in population-based registries.[@b12-clep-4-039],[@b13-clep-4-039] The proportion of patients with incomplete lung cancer stage in these registries increased with older age, as well as those that lived alone and were of black ethnicity.

The Danish Cancer Registry (DCR)[@b14-clep-4-039],[@b15-clep-4-039] is a nationwide registry that has recorded cancer incidence in the Danish population since 1943. Cancer diagnoses have been recorded according to the International Classification of Disease, 10th revision (ICD-10), since 2004. Stage at diagnosis has been recorded according to the 6th edition of TNM classification[@b16-clep-4-039] since 2004 and the 7th edition since 2009.

Completeness of TNM staging in the DCR is unknown. We therefore studied TNM completeness of SCLC and NSCLC, as well as conducted stratified analyses by year of diagnosis, gender, age, and level of comorbidity. Additionally, we suggest a method for defining stage categories in the presence of specific missing T, N, or M components.

Material and methods
====================

We performed this study in Denmark, which has a population of approximately 5.4 million. All residents are provided with tax-supported medical care which is free of charge. Since 1968, the Danish Civil Registration System has assigned a unique 10-digit personal identification number to all Danish residents.[@b17-clep-4-039] This number is used in all Danish registers and allows unambiguous individual-level data linkage.

Identification and categorization of lung cancer patients
---------------------------------------------------------

We identified all patients with a first-time lung cancer diagnosis (ICD-10 code C33-C34) recorded between January 1, 2004 and December 31, 2009 in the DCR. Patients were categorized according to histopathological (morphological) diagnosis in the DCR, which is derived from the Danish Pathology Register and recorded according to the International Classification of Diseases for Oncology, 3rd version (ICD-0-3) and combined with a topographic diagnosis code.[@b14-clep-4-039],[@b18-clep-4-039] We defined SCLC as cases with morphology codes 80413--80459, while NSCLC was defined as any other morphology code including those with no available histopathological diagnosis.

We designed an algorithm allowing assignment of stage categories, despite specific missing T, N, or M values. We categorized SCLC tumors as limited (if tumor was M0), extensive disease (if tumor was M1), or unknown (if tumor was Mx), regardless of the values, known or unknown, of other components (T and N) (Appendix 1). We categorized NSCLC tumors into limited, extensive, distant disease, and unknown (Appendix 1). If TNM stage included component values of T4, N3, or M1, tumor stage was categorized as IIIb or IV, and these tumors were categorized as distant. This was done regardless of the stage, known or unknown, of other components. All other cancers with missing components were categorized as unknown.

Comorbidity
-----------

We obtained data regarding comorbidity from the Danish National Patient Register (DNPR).[@b19-clep-4-039] This register contains data regarding all admissions to non-psychiatric hospitals in Denmark since 1978 and outpatient settings since 1995. The data includes dates of admission/contact, discharge, and diagnosis codes according to the ICD-10. The presence of comorbidity was defined according to the Charlson Comorbidity Index[@b20-clep-4-039],[@b21-clep-4-039] (CCI), and categorized as low (CCI = 0), medium (CCI = 1--2), or high (CCI \> 2) level of comorbidity. The CCI was based on all hospital diagnoses recorded in the DNPR within 10 years preceding the date of cancer diagnosis.

Statistical analysis
--------------------

We computed completeness and corresponding 95% confidence intervals (CI) for the TNM registration overall and for each component (ie, T, N, and M). Completeness was defined as the number of individuals with TNM recordings divided by the total number of patients. We stratified completeness according to year of cancer diagnosis, gender, age at diagnosis (0--39 years, 40--59 years, 60--79 years, or ≥80 years), and level of comorbidity. We computed completeness separately for SCLC and NSCLC and, for NSCLC, for histologically verified disease. SCLC diagnosis had been verified histologically. We repeated the analyses using the algorithm for stage assignment in the presence of specific missing T, N, or M values. Analyses were performed using SAS (v 9.2; SAS Institute, Inc, Cary, NC, USA).

Results
=======

We identified 24,734 patients (50% males) that had lung cancer in Denmark between 2004 and 2009. Of these, 3,658 (15%) had SCLC ([Table 1](#t1-clep-4-039){ref-type="table"}) and 21,076 (85%) had NSCLC ([Table 2](#t2-clep-4-039){ref-type="table"}). Among those with NSCLC, 17,972 (85%) cases had been histologically verified. Median age at diagnosis was 69 years for all patients combined. The proportion of patients with preexisting hospital recorded comorbidity was similar between the two patient categories (47% among patients with SCLC, 50% among patients with NSCLC).

Overall completeness of the TNM staging was 77.5% (95% confidence interval (CI): \[76.1%--78.8%\]) for SCLC and 77.9% (95% CI: \[77.3%--78.4%\]) for NSCLC. Overall completeness for NSCLC with histological verification was 83.3% (95% CI: \[82.8%--83.9%\]) (data not shown). During the study period, completeness increased from 75.9% (95% CI: \[72.2%--79.3%\]) to 83.4% (95% CI: \[80.3%--86.2%\]) for patients with SCLC and from 77.2% (95% CI: \[75.8%--78.6%\]) to 82.4% (95% CI: \[81.2%--83.6%\]) for patients with NSCLC ([Tables 1](#t1-clep-4-039){ref-type="table"} and [2](#t2-clep-4-039){ref-type="table"}).

Completeness did not vary by gender. However, among patients with SCLC, completeness declined from 78.5% (95% CI: \[76.9%--80.1%\]) among those aged 60--79 years to 67.1% (95% CI: \[62.1%--71.9%\]) among those aged 80 years or more. For patients with NSCLC, completeness declined from 80.8% (95% CI: \[80.2%--81.5%\]) among those aged 60--79 years to 59.9% (95% CI: \[58.2%--61.5%\]) among those aged 80 years or more. Completeness did not vary significantly between age groups 0--39, 40--59 or 60--79 years for SCLC or NSCLC.

Completeness also decreased with comorbidity level. The proportions of complete TNM staging were 81%, 76%, and 69% for low, medium, and high levels of comorbidity among patients with SCLC. The corresponding proportions were 81%, 76%, and 70% for patients with NSCLC.

Finally, we evaluated stage completeness for SCLC and NSCLC, allowing for the inclusion of missing TNM components as described above. When using this algorithm, overall stage completeness was 93.1% for SCLC and 91.1% for NSCLC. However, variations in completeness according to gender, age, year of diagnosis, and comorbidity showed a pattern similar to that of the original data ([Tables 3](#t3-clep-4-039){ref-type="table"} and [4](#t4-clep-4-039){ref-type="table"}).

Discussion
==========

We found that the completeness of TNM staging for SCLC and NSCLC in the DCR was lower for elderly patients and/or those with severe comorbidity. Completeness increased during the study period (2004--2009) and did not vary by lung cancer subtype or gender. Among patients with NSCLC, completeness was higher for patients with a histologically verified diagnosis than for those without such diagnosis.

Some SCLC as NSCLC cases without morphological information may have been misclassified. However, this potential misclassification likely had minor impact on the results, since we observed nearly the same completeness for SCLC as for NSCLC.

Completeness of lung cancer staging in the National Cancer Institute's (US) Surveillance, Epidemiology, and End Results (SEER) Program[@b12-clep-4-039] and completeness of the Swedish Cancer Register[@b13-clep-4-039] are higher than that of the DCR. Institutions participating in the SEER are financially rewarded, and SEER promotes education and conducts regular audits for cancer registration,[@b22-clep-4-039] which may explain this higher completeness. However, neither report presented overall estimates nor information regarding which components of TNM were missing or the impact of cancer type (SCLC or NSCLC), diagnosis year, or comorbidity on the likelihood of proper TNM staging.

Our findings are consistent with those of previous studies examining unstaged malignant disease which showed that fragile, elderly and/or those requiring nursing care are more likely to have unstaged disease.[@b13-clep-4-039],[@b23-clep-4-039],[@b24-clep-4-039] This is the first study to present TNM staging according to comorbidity levels.

In conclusion, overall completeness of the TNM registration of SCLC and NSCLC in the DCR is high, and the amount of incomplete data is likely to have a minor impact on studies examining prognosis or surveillance that rely on DCR data, particularly when evaluating potential sources of bias such as age and level of comorbidity. We further showed that overall stage completeness can be increased by including patients for which the TNM components provide unambiguous prognostic information, despite missing or misclassified information of individual staging components. Completeness of both SCLC and NSCLC registration decreased with increasing age and comorbidity level, but was not affected by gender or lung cancer subtype. Future studies examining treatment, prognosis, or screening policies that rely on TNM data from the DCR should be conducted to address these potential sources of bias.
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Stage categories for SCLC and NSCLC allowing for specific missing T, N, or M values
===================================================================================

Small cell lung cancer
----------------------

Limited disease

T0--4,x N0--3,x M0

Extensive disease

T0--4,x N0--3,x M1

Unknown

T0--4,x N0--N3,x Mx

Non-small cell lung cancer
--------------------------

Limited disease

T0--2 N0--1 M0 = Stadium IA--IIB

Extensive disease

T0--2 N2 M0 = Stadium IIIA

T3 N0--2 M0 = Stadium IIIA (& IIB)

Distant disease

T4 N0--3,x M0,x = Stadium IV

T0--3,x N3 M0,x = Stadium IIIB

T0--4,x N0--3,x M1 = Stadium IV

Unknown

Tx N0--2,x M0,x

T0--3 Nx M0

T0--3 N0--2,x Mx

###### 

Completeness of TNM registration for 3658 patients with small cell lung cancer according to year of diagnosis, gender, age, and level of comorbidity

                         TNM completeness   T completeness   N completeness   M completeness   Total                                                 
  ---------------------- ------------------ ---------------- ---------------- ---------------- ------------- ------------ ------------- ------------ ------
  Year of diagnosis                                                                                                                                  
   2004                  75.9 (421)         72.2--79.3       87.7 (487)       84.8--90.3       80.9 (449)    77.5--84.0   92.6 (514)    90.2--94.6   555
   2005                  76.0 (469)         72.5--79.3       85.7 (529)       82.8--88.3       81.5 (503)    78.3--84.4   92.2 (569)    89.9--94.1   617
   2006                  75.5 (468)         72.0--78.8       85.5 (530)       82.6--88.1       81.6 (506)    78.4--84.5   91.9 (570)    89.6--93.9   620
   2007                  75.3 (484)         71.8--78.5       84.6 (544)       81.7--87.2       80.7 (519)    77.5--83.6   92.4 (594)    90.1--94.2   643
   2008                  78.7 (474)         75.3--81.9       90.4 (544)       87.8--92.5       85.4 (514)    82.4--88.0   93.5 (563)    91.3--95.3   602
   2009                  83.4 (518)         80.3--86.2       91.0 (565)       88.5--93.1       89.0 (553)    86.4--91.3   95.8 (595)    94.0--97.2   621
  Gender                                                                                                                                             
   Female                76.9 (1359)        74.9--78.8       87.5 (1546)      85.9--89.0       83.1 (1468)   81.3--84.8   92.5 (1635)   91.2--93.7   1767
   Male                  78.0 (1475)        76.1--79.8       87.4 (1653)      86.0--88.9       83.3 (1576)   81.6--85.0   93.6 (1770)   92.4--94.6   1891
  Age                                                                                                                                                
   0--39 years           85.7 (6)           49.9--98.4       100 (7)          70.8--100        85.7 (6)      49.9--98.4   100 (7)       70.8--100    7
   40--59 years          78.7 (548)         75.6--81.7       88.2 (614)       85.7--90.5       83.6 (582)    80.7--86.2   95.5 (665)    93.8--96.9   696
   60--79 years          78.5 (2043)        76.9--80.1       88.0 (2290)      86.7--89.2       84.2 (2192)   82.8--85.6   93.7 (2437)   92.7--94.6   2602
   ≥80 years             67.1 (237)         62.1--71.9       81.6 (288)       77.3--85.4       74.8 (264)    70.1--79.1   83.9 (296)    79.8--87.4   353
  Level of comorbidity                                                                                                                               
   0                     80.5 (1576)        78.7--82.2       89.7 (1755)      88.3--91.0       85.6 (1675)   84.0--87.1   94.7 (1854)   93.7--95.7   1957
   1--2                  75.6 (961)         73.2--77.9       86.5 (1099)      84.5--88.3       81.7 (1038)   79.5--83.7   92.0 (1169)   90.4--93.4   1271
   ≥3                    69.1 (297)         64.6--73.3       80.2 (345)       76.3--83.8       77.0 (331)    72.8--80.8   88.8 (382)    85.6--91.6   430
  Total                  77.5 (2834)        76.1--78.8       87.5 (3199)      86.4--88.5       83.2 (3044)   82.0--84.4   93.1 (3405)   92.2--93.9   3658

###### 

Completeness of TNM registration for 21,076 patients with non-small cell lung cancer according to year of diagnosis, gender, age, and level of comorbidity

                         TNM completeness   T completeness   N completeness   M completeness   Total                                                    
  ---------------------- ------------------ ---------------- ---------------- ---------------- -------------- ------------- -------------- ------------ -------
  Year of diagnosis                                                                                                                                     
   2004                  77.2 (2594)        75.8--78.6       87.2 (2927)      86.0--88.3       80.6 (2707)    79.3--81.9    88.0 (2956)    86.9--89.1   3358
   2005                  75.6 (2543)        74.1--77.0       86.6 (2913)      85.4--87.7       79.7 (2681)    78.3--81.0    88.9 (2993)    87.9--90.0   3365
   2006                  74.0 (2549)        72.5--75.4       84.8 (2922)      83.6--86.0       78.1 (2692)    76.7--79.5    87.1 (3003)    86.0--88.2   3446
   2007                  76.7 (2797)        75.3--78.0       89.0 (3246)      87.9--89.9       81.5 (2974)    80.2--82.7    90.2 (3290)    89.2--91.1   3649
   2008                  81.0 (2903)        79.7--82.2       91.1 (3265)      90.1--92.0       85.9 (3078)    84.7--87.0    92.2 (3304)    91.3--93.0   3585
   2009                  82.4 (3027)        81.2--83.6       91.9 (3376)      91.0--92.8       86.8 (3190)    85.7--87.9    92.1 (3383)    91.2--92.9   3673
  Gender                                                                                                                                                
   Female                77.6 (7605)        76.8--78.4       88.4 (8661)      87.7--89.0       82.0 (8035)    81.2--82.7    89.5 (8775)    88.9--90.1   9800
   Male                  78.1 (8808)        77.3--78.9       88.6 (9988)      88.0--89.2       82.4 (9287)    81.7--83.1    90.0 (10154)   89.5--90.6   11276
  Age                                                                                                                                                   
   0--39 years           83.7 (82)          75.4--90.0       89.8 (88)        82.7--94.6       87.8 (86)      80.2--93.1    95.9 (94)      90.6--98.6   98
   40--59 years          82.9 (3224)        81.7--84.1       91.4 (3553)      90.5--92.3       87.1 (3384)    86.0--88.1    94.8 (3683)    94.0--95.4   3887
   60--79 years          80.8 (11085)       80.2--81.5       90.5 (12413)     90.0--91.0       84.8 (11630)   84.2--85.4    91.9 (12607)   91.5--92.4   13715
   ≥80 years             59.9 (2022)        58.2--61.5       76.9 (2595)      75.4--78.3       65.8 (2222)    64.2--67.4    75.4 (2545)    73.9--76.8   3376
  Level of comorbidity                                                                                                                                  
   0 81.1 (8535)         80.4--81.9         90.5 (9524)      90.0--91.1       85.1 (8953)      84.4--85.8     92.6 (9744)   92.1--93.1     10521        
   1--2                  76.4 (5868)        75.5--77.4       87.6 (6729)      86.9--88.4       80.8 (6203)    79.9--81.7    88.2 (6775)    87.5--89.0   7678
   ≥3                    69.9 (2010)        68.2--71.5       83.3 (2396)      81.9--84.6       75.3 (2166)    73.7--76.8    83.8 (2410)    82.4--85.1   2877
  Total                  77.9 (16413)       77.3--78.4       88.5 (18649)     88.1--88.9       82.2 (17322)   81.7--82.7    89.8 (18929)   89.4--90.2   21076

###### 

Patients with limited, extensive, or unknown stage of small cell lung cancer according to year of diagnosis, gender, age, and level of comorbidity

                         Limited disease   Extensive disease   Unknown                
  ---------------------- ----------------- ------------------- --------- ------ ----- ------
  Year of diagnosis                                                                   
   2004                  153               27.6                361       65.0   41    7.4
   2005                  176               28.5                393       63.7   48    7.8
   2006                  149               24.0                421       67.9   50    8.1
   2007                  168               26.1                426       66.3   49    7.6
   2008                  160               26.6                403       66.9   39    6.5
   2009                  152               24.5                443       71.3   26    4.2
  Gender                                                                              
   Female                467               26.4                1168      66.1   132   7.5
   Male                  491               26.0                1279      67.6   121   6.4
  Age                                                                                 
   0--39 years           2                 28.6                5         71.4   0     0
   40--59 years          191               27.4                474       68.1   31    4.5
   60--79 years          696               26.7                1741      66.9   165   6.3
   ≥80 years             69                19.5                227       64.3   57    16.1
  Level of comorbidity                                                                
   0                     566               28.9                1288      65.8   103   5.3
   1--2                  297               23.4                872       68.6   102   8.0
   ≥3                    95                22.1                287       66.7   48    11.2
  Total                  958               26.2                2447      66.9   253   6.9

###### 

Patients with limited, extensive, disseminated, or unknown stage of non-small cell lung cancer, according to year of diagnosis, gender, age, and level of comorbidity

                         Limited disease   Extensive disease   Disseminated disease   Unknown                         
  ---------------------- ----------------- ------------------- ---------------------- --------- ------- ------ ------ ------
  Year of diagnosis                                                                                                   
   2004                  519               15.5                294                    8.8       2171    64.7   374    11.1
   2005                  521               15.5                337                    10.0      2157    64.1   350    10.4
   2006                  447               13.0                309                    9.0       2303    66.8   387    11.2
   2007                  560               15.3                316                    8.7       2467    67.6   306    8.4
   2008                  521               14.5                331                    9.2       2510    70.0   223    6.2
   2009                  551               15.0                393                    10.7      2488    67.7   241    6.6
  Gender                                                                                                              
   Female                1526              15.6                866                    8.8       6524    66.6   884    9.0
   Male                  1593              14.1                1114                   9.9       7572    67.2   997    8.8
  Age                                                                                                                 
   0--39 years           18                18.4                7                      7.1       68      69.4   5      5.1
   40--59 years          542               13.9                373                    9.6       2816    72.4   156    4.0
   60--79 years          2177              15.9                1344                   9.8       9252    67.5   942    6.9
   ≥80 years             382               11.3                256                    7.6       1960    58.1   778    23.0
  Level of comorbidity                                                                                                
   0                     1396              13.3                1005                   9.6       7465    71.0   655    6.2
   1--2                  1242              16.2                709                    9.2       4919    64.1   808    10.5
   ≥3                    481               16.7                266                    9.2       1712    59.5   418    14.5
  Total                  3119              14.8                1980                   9.4       14096   66.9   1881   8.9
